ARCHIVES

Drug Development: FDA Grants Breakthrough Therapy Designation To CTL019 in ALL

This article is from The Cancer Letter archive.

Vol. 40 No. 24 | June 11, 2014

Download PDF Visit The Full Archive

Related Articles

Cancer Act 25th Year: cancer Mortality Rate Began decline In 1990s, NCI, ACS Studies Find

November 22, 1996

Endostatin Enters Phase II Trial For Neuroendocrine Tumors.

December 14, 2001

NCI Branch Chiefs, ACCI Join Support For DeVita

June 25, 1981

Bill Requires NIH-Funded Researchers To Send Manuscripts To PubMed Central.

November 2, 2007

Foon To Direct Barrett Center; Hundahl Leads Commission

March 5, 1999

Clinical Trials Approved By NCI CTEP Last Month

July 29, 2011